(NASDAQ: AYTU) Aytu Biopharma's forecast annual revenue growth rate of 12.6% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.36%.
Aytu Biopharma's revenue in 2026 is $62,640,000.On average, 5 Wall Street analysts forecast AYTU's revenue for 2026 to be $618,522,577, with the lowest AYTU revenue forecast at $553,543,736, and the highest AYTU revenue forecast at $687,461,972. On average, 5 Wall Street analysts forecast AYTU's revenue for 2027 to be $891,360,725, with the lowest AYTU revenue forecast at $737,070,860, and the highest AYTU revenue forecast at $1,151,780,550.
In 2028, AYTU is forecast to generate $1,034,563,186 in revenue, with the lowest revenue forecast at $993,991,660 and the highest revenue forecast at $1,064,991,831.